Literature DB >> 23728704

Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients.

Tjalf Ziemssen1, Raimar Kempcke, Marco Eulitz, Lars Großmann, Alexander Suhrbier, Katja Thomas, Thorsten Schultheiss.   

Abstract

The long disease duration of multiple sclerosis and the increasing therapeutic options require a individualized therapeutic approach which should be carefully documented over years of observation. To switch from MS documentation to an innovative MS management, new computer- and internet-based tools could be implemented as we could demonstrate with the novel computer-based patient management system "multiple sclerosis management system 3D" (MSDS 3D). MSDS 3D allows documentation and management of visit schedules and mandatory examinations via defined study modules by integration of data input from various sources (patients, attending physicians and MS nurses). It provides forms for the documentation of patient visits as well as clinical and diagnostic findings. Information can be collected via interactive touch screens. Specific modules allow the management of highly efficacious treatments as natalizumab or fingolimod. MSDS can be used to transfer the documented data to databases as, e.g. the registry of the German MS society or REGIMS. MSDS has already been implemented successfully in clinical practice and is currently being evaluated in a multicenter setting. High-quality management and documentation are crucial for improvements in clinical practice and research work.

Entities:  

Mesh:

Year:  2013        PMID: 23728704     DOI: 10.1007/s00702-013-1041-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  19 in total

Review 1.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

2.  [MS registry in Germany--design and first results of the pilot phase].

Authors:  P Flachenecker; U K Zettl; U Götze; J Haas; S Schimrigk; W Elias; M Pette; M Eulitz; M Hennig; J Bertram; R Hollweck; A Neiss; M Daumer; D Pitschnau-Michel; P Rieckmann
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 3.  From genes to function: the next challenge to understanding multiple sclerosis.

Authors:  Lars Fugger; Manuel A Friese; John I Bell
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

4.  Modern communication technology skills of patients with multiple sclerosis.

Authors:  Rocco Haase; Thorsten Schultheiss; Raimar Kempcke; Katja Thomas; Tjalf Ziemssen
Journal:  Mult Scler       Date:  2013-02-06       Impact factor: 6.312

5.  Symptom management in patients with multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol Sci       Date:  2011-12       Impact factor: 3.181

Review 6.  [Multiple sclerosis management system 3D. Moving from documentation towards management of patients].

Authors:  T Schultheiss; R Kempcke; F Kratzsch; M Eulitz; M Pette; H Reichmann; T Ziemssen
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

7.  Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis.

Authors:  J N Whitaker; G W Mitchell; G R Cutter
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

8.  Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.

Authors:  Charity Evans; Jennifer Tam; Elaine Kingwell; Joel Oger; Helen Tremlett
Journal:  Clin Ther       Date:  2012-01-31       Impact factor: 3.393

9.  [The Multiple Sclerosis Documentation System MSDS. Discussion of a documentation standard for multiple sclerosis].

Authors:  M Pette; M Eulitz
Journal:  Nervenarzt       Date:  2002-02       Impact factor: 1.214

Review 10.  The challenge of managing patients with multiple sclerosis.

Authors:  Rhona MacLean
Journal:  Nurs Times       Date:  2004 Jan 27-Feb 2
View more
  18 in total

Review 1.  [Real-world evidence : Benefits and limitations in multiple sclerosis research].

Authors:  T Ziemssen; D Rothenbacher; J Kuhle; T Berger
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

Review 2.  Standardization and digitization of clinical data in multiple sclerosis.

Authors:  Marcus D'Souza; Athina Papadopoulou; Christophe Girardey; Ludwig Kappos
Journal:  Nat Rev Neurol       Date:  2021-01-15       Impact factor: 42.937

3.  The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.

Authors:  Tjalf Ziemssen; Raimar Kern; Christian Cornelissen
Journal:  BMC Neurol       Date:  2015-06-18       Impact factor: 2.474

4.  A computer-based screening method for distress in patients with multiple sclerosis: a feasibility study.

Authors:  Rosa E Boeschoten; Bernard Mj Uitdehaag; Patricia van Oppen; Vincent de Groot; Emma H Collette; Kim Aa Bakker; Chris H Polman; Joost Dekker
Journal:  JMIR Res Protoc       Date:  2014-06-04

5.  The importance of collecting structured clinical information on multiple sclerosis.

Authors:  Tjalf Ziemssen; Jan Hillert; Helmut Butzkueven
Journal:  BMC Med       Date:  2016-05-31       Impact factor: 8.775

Review 6.  Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach.

Authors:  Tjalf Ziemssen; Raimar Kern; Katja Thomas
Journal:  BMC Neurol       Date:  2016-08-02       Impact factor: 2.474

Review 7.  Optimizing treatment success in multiple sclerosis.

Authors:  Tjalf Ziemssen; Tobias Derfuss; Nicola de Stefano; Gavin Giovannoni; Filipe Palavra; Davorka Tomic; Tim Vollmer; Sven Schippling
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

8.  Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.

Authors:  Tjalf Ziemssen; Raimar Kern; Christian Cornelissen
Journal:  BMC Neurol       Date:  2016-08-08       Impact factor: 2.474

9.  New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

Authors:  T Sehr; U Proschmann; K Thomas; M Marggraf; E Straube; H Reichmann; A Chan; T Ziemssen
Journal:  J Neuroinflammation       Date:  2016-06-27       Impact factor: 8.322

10.  Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System.

Authors:  Raimar Kern; Rocco Haase; Judith Christina Eisele; Katja Thomas; Tjalf Ziemssen
Journal:  Interact J Med Res       Date:  2016-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.